Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.

Front Oncol · 2026 · PMC13193838 · PMID 42180117

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the indirect comparison, Osi+CT showed a numerical PFS advantage over Ami+Laz, although the difference did not reach statistical significance (HR 0.79, 95% CI 0.61–1.04).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.